Latest Earnings Results: Q2 '26
Estimated EPS
-$2.64
Reported EPS
-$2.44
Surprise
+7.66%
Estimated Rev
$7.72M
Reported Rev
$13.54M
Surprise
+75.38%
• Reported GAAP EPS of -$2.44 up 36.79% YoY • Reported revenue of $13.54M up 577.88% YoY
Bullish Takeaway
Tonix Pharmaceuticals achieved significant growth in TONMYA net sales and prescription volumes, while the company successfully expanded payer coverage and progressed key clinical pipeline programs for its drug candidates.
Bearish Takeaway
Tonix Pharmaceuticals experienced a widened net loss and increased operating expenses, while the company remains subject to significant commercialization, financing, and regulatory risks inherent in its biopharmaceutical business model.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$2.48 | -- | -- | N/A |
Q2 '26 | -$2.64 | -$2.44 | 7.66% | BEAT |
Q1 '26 | -$2.57 | -$2.93 | -14.01% | MISSED |
Q4 '25 | -$3.19 | -$3.98 | -24.76% | MISSED |
Q3 '25 | -$3.59 | -$3.59 | -0.14% | MISSED |